Britain approves Novavax COVID-19 shot for 12-17 year-olds
Britain in February cleared Novavax's two-dose vaccine, Nuvaxovid, for use in adults.
- Aug 26, 2022,
- Updated Aug 26, 2022 4:51 PM IST
Britain's medicines regulator on Friday approved Novavax's COVID-19 vaccine for children aged between 12 and 17 years.
The mRNA vaccines made by Moderna as well as the partnership between Pfizer-BioNTech are also cleared for use by this age group, the Medicines and Healthcare products Regulatory Agency (MHRA) said.
Britain in February cleared Novavax's two-dose vaccine, Nuvaxovid, for use in adults.
Britain's medicines regulator on Friday approved Novavax's COVID-19 vaccine for children aged between 12 and 17 years.
The mRNA vaccines made by Moderna as well as the partnership between Pfizer-BioNTech are also cleared for use by this age group, the Medicines and Healthcare products Regulatory Agency (MHRA) said.
Britain in February cleared Novavax's two-dose vaccine, Nuvaxovid, for use in adults.